InsiderTrades

Form 4 for ATTO Attovia Therapeutics, Inc.

Accepted 2026-08-07 15:45:54 ET · period of report 2026-08-06 · accession 0001193125-26-340173 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2026-08-07 15:45 2026-08-06 ATTO Sanofi 10% C - Cnv Deriv — +782.9K 782.9K New —
DI 2026-08-07 15:45 2026-08-06 ATTO Sanofi 10% P - Purchase $17.00 +300.0K 1.08M +38% +$5.10M
DI 2026-08-07 15:45 2026-08-06 ATTO Sanofi 10% C - Cnv Deriv — -782.9K 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-08-06 C A 782,855 — 782,855 I See footnote — — (F1) The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
2 Common Common Stock 2026-08-06 P A 300,000 $17.00 1,082,855 I See footnote — — (F2) Represents a purchase in the Issuer's IPO. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
3 Derivative Series C Preferred Stock 2026-08-06 C D 782,855 — 0 I See footnote — · — to — 782,855 Common Stock (F1) The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026. (F1) The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026. (F1) The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026. (F1) The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026. (F1) The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.